Table 3.

Univariate analysis of prognostic factors associated with LPFS in patients with ESCC treated with chemoradiotherapy

Variables	Training cohort p			Validation cohort p
	HR	95% CI	p	HR	95% CI	p
Age	0.987	0.967–1.007	0.202	0.984	0.957–1.011	0.252
Gender	1.639	1.014–2.650	0.044	1.198	0.652–2.202	0.560
Tumor location	1.120	0.851–1.473	0.419	1.289	0.917–1.812	0.143
T stage	2.015	1.453–2.793	< 0.001	1.943	1.227–3.077	0.005
N stage	1.867	1.446–2.410	< 0.001	1.765	1.215–2.563	0.003
Clinical stage	2.194	1.581–3.044	< 0.001	2.309	1.440–3.704	0.001
Radiation dose	0.965	0.923–1.009	0.118	0.996	0.921–1.078	0.927
LDH	1.641	1.116–2.414	0.012	1.369	0.778–2.408	0.276
NLR	1.069	0.965–1.184	0.199	1.015	0.901–1.142	0.810
PLR	1.001	0.999–1.003	0.177	1.001	0.999–1.004	0.377
CR status	0.128	0.072–0.228	< 0.001	0.295	0.157–0.556	< 0.001